{"id":"W4398564850","doi":"10.1093/ndt/gfae069.434","title":"#145 Subgroup and secondary endpoint evaluation of a phase 2 randomized placebo-controlled trial of ravulizumab in IgA nephropathy","year":2024,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Placebo; Clinical endpoint; Nephropathy; Subgroup analysis; Medicine; Phase (matter); Randomized controlled trial; Internal medicine; Physics; Meta-analysis; Pathology; Alternative medicine; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007251602,0.002471578,0.004626985,0.0007571165,0.0006922692,0.001603471,0.0009214578,0.001998701,0.01140704],"category_scores_gemma":[0.005773583,0.0008056202,0.005480147,0.0006040127,0.0007790434,0.001300948,0.0007872828,0.002509995,0.0009769468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009711675,"about_ca_system_score_gemma":0.001547832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007124039,"about_ca_topic_score_gemma":0.002331659,"domain_scores_codex":[0.9947242,0.003619645,0.0004435752,0.0005885247,0.0003416494,0.0002823939],"domain_scores_gemma":[0.9979868,0.000573943,0.0005620658,0.0002754192,0.0002964947,0.000305323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.981768,0.001140286,0.000691065,0.001365429,0.006671136,0.00004280649,0.00002964248,0.000167539,0.00119661,0.0001640005,0.001377493,0.005385902],"study_design_scores_gemma":[0.9631745,0.02703676,0.002761273,0.00009453801,0.004268223,0.00002697799,0.0000233975,0.0003447556,0.0002741424,0.0003373214,0.001635537,0.00002265505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8737822,0.03396533,0.005090357,0.004521451,0.006796013,0.04972088,0.01378698,0.0006117579,0.01172501],"genre_scores_gemma":[0.9367729,0.004870018,0.004319678,0.003992352,0.002949652,0.03450973,0.005251344,0.0000776243,0.007256655],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01140704,"threshold_uncertainty_score":0.03835064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01266103678535745,"score_gpt":0.2999930676838363,"score_spread":0.2873320308984789,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}